NCOG-66. ‘Core outcome set’ for leptomeningeal disease (LeptoCOS): a multi-disciplinary, international, consensus effort

Le résumé fourni par la source

Abstract BACKGROUND Leptomeningeal disease (LMD) represents a stage of metastatic cancer when tumor cells have seeded the leptomeninges and cerebrospinal fluid (CSF)-containing subarachnoid space. Despite decades of efforts by the neuro-oncology community, response assessment remains challenging, and the prognosis of this whole neuroaxial disease remains extremely poor, ranging typically between 3-8 months despite standard of care therapy. The extensive heterogeneity in outcomes observed in randomized controlled trials (RCTs) for LMD has been thoroughly documented by prior consensus reviews and systematic reviews, warranting the development and implementation of a standardized core outcome set (COS) for LMD. Objective: This ongoing project aims to develop a COS for LMD (LeptoCOS) through a multidisciplinary, international effort, following current methodological recommendations. METHODS The LeptoCOS collaborative has been established in order to develop COS for use in clinical effectiveness trials of LMD, including RCTs and NRTs, through a collaboratorship framework working with multiple stakeholder groups and to help drive its global adoption. This project has been pre-registered with Core Outcome Measures in Effectiveness Trials (COMET) database (COMET registration ID 3224) database: https://www.comet-initiative.org/Studies/Details/3224. COS are being developed following Core Outcome Set–Standards for Development (COS-STAD) and COMET guidelines. RESULTS Long-list of outcomes of potential relevance are being generated based on updated systematic review of published literature and searches of trial registries (rapid review). After eDelphi process and consensus meetings with various stakeholders, short-list of outcomes will be generated for inclusion and the final LeptoCOS (for discussion/presentation at the conference). CONCLUSIONS With the endorsement of professional societies and non-profit organizations, this effort will help standardize the use and reporting of outcomes reported in future clinical studies of LMD, thereby enabling efficient evidence synthesis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.